Cover Image

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL

Chronic myeloid leukaemia (CML) is a malignant disease of the bone marrow characterised by the presence of the Philadelphia (Ph) chromosome. About 20% of acute lymphoblastic leukaemia (ALL) patients also show this genetic abnormality. A new drug, imatinib (Glivec®, Novartis Pharma AG, Basel, Switzer...

Full description

Saved in:
Bibliographic Details
Main Authors: Schiffer, Charles A. (Author) , Hehlmann, Rüdiger (Author) , Larson, Richard A. (Author)
Format: Article (Journal)
Language:English
Published: 08 April 2003
In: Leukemia
Year: 2003, Volume: 17, Issue: 4, Pages: 691-699
ISSN:1476-5551
DOI:10.1038/sj.leu.2402879
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2402879
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2402879
Get full text
Author Notes:C.A. Schiffer, R. Hehlmann and R. Larson

MARC

LEADER 00000caa a2200000 c 4500
001 1801674310
003 DE-627
005 20230426073513.0
007 cr uuu---uuuuu
008 220512s2003 xx |||||o 00| ||eng c
024 7 |a 10.1038/sj.leu.2402879  |2 doi 
035 |a (DE-627)1801674310 
035 |a (DE-599)KXP1801674310 
035 |a (OCoLC)1341459970 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schiffer, Charles A.  |e VerfasserIn  |4 aut 
245 1 0 |a Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL  |c C.A. Schiffer, R. Hehlmann and R. Larson 
264 1 |c 08 April 2003 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.05.2022 
520 |a Chronic myeloid leukaemia (CML) is a malignant disease of the bone marrow characterised by the presence of the Philadelphia (Ph) chromosome. About 20% of acute lymphoblastic leukaemia (ALL) patients also show this genetic abnormality. A new drug, imatinib (Glivec®, Novartis Pharma AG, Basel, Switzerland, and formerly STI571) is having a profound effect on the treatment and management of all stages of CML and Philadelphia chromosome positive (Ph+) ALL. New treatment algorithms are being developed. Should imatinib replace or be combined with existing therapies? To address this question, we review the pros and cons of therapy with interferon-α (IFN-α), allogeneic transplantation, autologous transplantation, imatinib, and in the case of Ph+ ALL, chemotherapy and experimental approaches. Conservative and aggressive treatments will be discussed and new molecular methods of monitoring cytogenetic response and their significance will also be reviewed. 
650 4 |a Cancer Research 
650 4 |a general 
650 4 |a Hematology 
650 4 |a Intensive / Critical Care Medicine 
650 4 |a Internal Medicine 
650 4 |a Medicine/Public Health 
650 4 |a Oncology 
700 1 |a Hehlmann, Rüdiger  |d 1941-  |e VerfasserIn  |0 (DE-588)1037003489  |0 (DE-627)751737879  |0 (DE-576)390939463  |4 aut 
700 1 |a Larson, Richard A.  |e VerfasserIn  |0 (DE-588)141991615  |0 (DE-627)632860189  |0 (DE-576)327252456  |4 aut 
773 0 8 |i Enthalten in  |t Leukemia  |d London : Springer Nature, 1997  |g 17(2003), 4, Seite 691-699  |h Online-Ressource  |w (DE-627)32046699X  |w (DE-600)2008023-2  |w (DE-576)094139733  |x 1476-5551  |7 nnas  |a Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL 
773 1 8 |g volume:17  |g year:2003  |g number:4  |g pages:691-699  |g extent:9  |a Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL 
856 4 0 |u https://doi.org/10.1038/sj.leu.2402879  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/2402879  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220512 
993 |a Article 
994 |a 2003 
998 |g 1037003489  |a Hehlmann, Rüdiger  |m 1037003489:Hehlmann, Rüdiger  |d 60000  |d 61200  |e 60000PH1037003489  |e 61200PH1037003489  |k 0/60000/  |k 1/60000/61200/  |p 2 
999 |a KXP-PPN1801674310  |e 4133256387 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"origin":[{"dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedDisp":"1997-"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2008023-2"],"eki":["32046699X"],"issn":["1476-5551"]},"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia","title_sort":"Leukemia"}],"recId":"32046699X","disp":"Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALLLeukemia","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Nachgewiesen 11.1997 -"],"note":["Gesehen am 15.03.04"],"part":{"year":"2003","volume":"17","text":"17(2003), 4, Seite 691-699","pages":"691-699","extent":"9","issue":"4"},"language":["eng"]}],"origin":[{"dateIssuedDisp":"08 April 2003","dateIssuedKey":"2003"}],"title":[{"title":"Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL","title_sort":"Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1038/sj.leu.2402879"],"eki":["1801674310"]},"physDesc":[{"extent":"9 S."}],"person":[{"role":"aut","family":"Schiffer","display":"Schiffer, Charles A.","given":"Charles A."},{"family":"Hehlmann","role":"aut","display":"Hehlmann, Rüdiger","given":"Rüdiger"},{"given":"Richard A.","display":"Larson, Richard A.","role":"aut","family":"Larson"}],"recId":"1801674310","note":["Gesehen am 12.05.2022"],"name":{"displayForm":["C.A. Schiffer, R. Hehlmann and R. Larson"]},"language":["eng"]} 
SRT |a SCHIFFERCHPERSPECTIV0820 

Similar Items